Welcome to the OMA Blog

Pediatric MASLD is rapidly rising alongside childhood obesity. This expert consensus outlines current evidence on epidemiology, diagnosis, and management, highlighting screening strategies and emerging therapies to guide early identification and care.

The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase Quality Improvement (QI) initiative designed to strengthen obesity care delivery across diverse outpatient clinical settings in the United States. OMA is also partnering with Q Synthesis LLC, a healthcare quality improvement company, to develop and implement key components of the initiative. At the heart of the program is the Implementation into Practice Collaborative (IPC) , a virtual learning collaborative that will run from February through May 2026.

A new study by Williamson et al. (2025) showed that adding a short sleep screening tool directly into the EHR helped primary care providers identify more sleep disorders and led to more PSG orders and specialty referrals. This is a simple, practical approach that could also be very useful in Obesity Medicine, where sleep screening is still often missed but could make a big impact

The Obesity Medicine Association (OMA) welcomes today’s announcement by the White House Administration regarding expanded access to obesity medications and a commitment to make effective treatment for the chronic disease of obesity more affordable and widely available.

For decades, the number on the scale has been treated as the ultimate benchmark of health. In clinical settings, weight reduction has often been framed as the primary outcome, and weight gain as failure. Yet, as obesity medicine advances, it is increasingly clear that this approach is incomplete and potentially counterproductive. Weight alone fails to capture the complexity of health and behavior change, while overemphasis on the scale can erode trust, reinforce stigma, and undermine long-term engagement (1–3).

A meta-analysis and systematic review of 18 trials including those published in the last 2 years to review primary efficacy outcomes, exploratory efficacy outcomes and safety outcomes. GLP-1 RAs significantly improve outcomes for children and adolescents with Type 2 Diabetes or obesity.

Learn how non-exercise activity thermogenesis (NEAT) supports obesity treatment and explore clinical guidance to boost patient outcomes.

The article warns against relying on lifestyle changes alone when safe, effective GLP-1s exist for pediatric obesity. It urges fair care that blends medical therapy with healthy habits, especially for children facing barriers to lifestyle change.

Explore a complete overview of hyperphagia, including common underlying conditions and emerging studies that all healthcare providers should be aware of.